Document is current

Article History

Received: 29 April 2022

Accepted: 17 June 2022

First Online: 22 August 2022

Change Date: 23 September 2022

Change Type: Update

Change Details: The first sentence in the introduction has been updated.

Declarations

:

: Both patients gave their written informed consent for participation. The approval by the ethics committee of the medical faculty of Eberhard-Karls University of Tübingen was not required.

: Both patients gave their written informed consent for publication.

: KF received funding for Lexi study from Boehringer-Ingelheim outside of the presented work. UZ has received grants from European Research Council, German Research Foundation, German Ministry of Education and Research, Biogen Idec GmbH, Servier, and Janssen Pharmaceuticals NV, all not related to this work; and consulting honoraria from Biogen Idec GmbH, Bayer Vital GmbH, Bristol-Myers Squibb GmbH, Pfizer, CorTec GmbH, Medtronic GmbH, all not related to this work. SP received speaker’s honoraria and consulting honoraria from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb/ Pfizer, Daiichi Sankyo, and Werfen, reimbursement for congress traveling and accommodation from Bayer and Boehringer-Ingelheim, and research support from Bristol-Myers Squibb/Pfizer (significant), Boehringer-Ingelheim, Daiichi Sankyo (significant), and Helena Laboratories (all other contributions: modest). All competing interest are outside the present work. BB is co-founder and share-holder of AIRAmed and has received consultancy fees from Medtronic, all outside of the submitted work. TL is co-founder, CEO and share-holder of AIRAmed, he has received grants from the Alzheimer Forschung Initiative e.V., travel grants from Bayer and presentation fees from Roche, all outside of the submitted work. AM, AF, MS, ML and JSP have no competing interests to declare.